Thompson Siegel & Walmsley’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.18M | Sell |
6,408
-29
| -0.5% | -$12.9K | 0.06% | 269 |
|
|
2026
Q1 | $2.87M | Sell |
6,437
-261
| -4% | -$122K | 0.05% | 265 |
|
|
2025
Q4 | $3.04M | Sell |
6,698
-105
| -2% | -$45.3K | 0.05% | 257 |
|
|
2025
Q3 | $2.66M | Sell |
6,803
-67
| -1% | -$28K | 0.04% | 262 |
|
|
2025
Q2 | $3.06M | Sell |
6,870
-239
| -3% | -$110K | 0.05% | 242 |
|
|
2025
Q1 | $3.45M | Sell |
7,109
-130
| -2% | -$60.6K | 0.06% | 217 |
|
|
2024
Q4 | $2.92M | Hold |
7,239
| – | – | 0.05% | 228 |
|
|
2024
Q3 | $3.37M | Sell |
7,239
-11
| -0.2% | -$5.28K | 0.05% | 231 |
|
|
2024
Q2 | $3.4M | Sell |
7,250
-134
| -2% | -$58.2K | 0.05% | 224 |
|
|
2024
Q1 | $3.09M | Sell |
7,384
-1,149
| -13% | -$486K | 0.05% | 232 |
|
|
2023
Q4 | $3.47M | Sell |
8,533
-167
| -2% | -$61.7K | 0.06% | 221 |
|
|
2023
Q3 | $3.02M | Sell |
8,700
-278
| -3% | -$97.2K | 0.05% | 227 |
|
|
2023
Q2 | $3.16M | Sell |
8,978
-634
| -7% | -$214K | 0.05% | 210 |
|
|
2023
Q1 | $3.03M | Sell |
9,612
-835
| -8% | -$250K | 0.05% | 210 |
|
|
2022
Q4 | $3.02M | Sell |
10,447
-789
| -7% | -$240K | 0.05% | 207 |
|
|
2022
Q3 | $3.25M | Sell |
11,236
-1,730
| -13% | -$498K | 0.06% | 203 |
|
|
2022
Q2 | $3.65M | Sell |
12,966
-7,822
| -38% | -$2.09M | 0.06% | 209 |
|
|
2022
Q1 | $5.42M | Sell |
20,788
-21,274
| -51% | -$5.05M | 0.08% | 202 |
|
|
2021
Q4 | $9.24M | Sell |
42,062
-3,039
| -7% | -$591K | 0.13% | 154 |
|
|
2021
Q3 | $8.18M | Buy |
45,101
+9,039
| +25% | +$1.76M | 0.12% | 161 |
|
|
2021
Q2 | $7.27M | Buy |
36,062
+34,742
| +2,632% | +$7.27M | 0.1% | 167 |
|
|
2021
Q1 | $284K | Buy |
1,320
+1,006
| +320% | +$221K | ﹤0.01% | 334 |
|
|
2020
Q4 | $74K | Sell |
314
-40
| -11% | -$9.18K | ﹤0.01% | 416 |
|
|
2020
Q3 | $96K | Hold |
354
| – | – | ﹤0.01% | 375 |
|
|
2020
Q2 | $103K | Hold |
354
| – | – | ﹤0.01% | 374 |
|
|
2020
Q1 | $84K | Sell |
354
-10
| -3% | -$2.29K | ﹤0.01% | 372 |
|
|
2019
Q4 | $80K | Buy |
364
+10
| +3% | +$2.02K | ﹤0.01% | 445 |
|
|
2019
Q3 | $60K | Hold |
354
| – | – | ﹤0.01% | 486 |
|
|
2019
Q2 | $65K | Hold |
354
| – | – | ﹤0.01% | 479 |
|
|
2019
Q1 | $65K | Hold |
354
| – | – | ﹤0.01% | 479 |
|
|
2018
Q4 | $59K | Hold |
354
| – | – | ﹤0.01% | 471 |
|
|
2018
Q3 | $68K | Hold |
354
| – | – | ﹤0.01% | 493 |
|
|
2018
Q2 | $60K | Hold |
354
| – | – | ﹤0.01% | 511 |
|
|
2018
Q1 | $58K | Hold |
354
| – | – | ﹤0.01% | 509 |
|
|
2017
Q4 | $53K | Buy |
354
+300
| +556% | +$44.4K | ﹤0.01% | 528 |
|
|
2017
Q3 | $8K | Hold |
54
| – | – | ﹤0.01% | 735 |
|
|
2017
Q2 | $7K | Hold |
54
| – | – | ﹤0.01% | 734 |
|
|
2017
Q1 | $6K | Sell |
54
-23
| -30% | -$2.02K | ﹤0.01% | 743 |
|
|
2016
Q4 | $6K | Buy |
77
+23
| +43% | +$1.87K | ﹤0.01% | 683 |
|
|
2016
Q3 | $5K | Hold |
54
| – | – | ﹤0.01% | 680 |
|
|
2016
Q2 | $5K | Hold |
54
| – | – | ﹤0.01% | 684 |
|
|
2016
Q1 | $4K | Hold |
54
| – | – | ﹤0.01% | 656 |
|
|
2015
Q4 | $7K | Hold |
54
| – | – | ﹤0.01% | 635 |
|
|
2015
Q3 | $6K | Hold |
54
| – | – | ﹤0.01% | 652 |
|
|
2015
Q2 | $7K | Hold |
54
| – | – | ﹤0.01% | 641 |
|
|
2015
Q1 | $6K | Hold |
54
| – | – | ﹤0.01% | 656 |
|
|
2014
Q4 | $6K | Hold |
54
| – | – | ﹤0.01% | 656 |
|
|
2014
Q3 | $6K | Sell |
54
-1,600
| -97% | -$152K | ﹤0.01% | 652 |
|
|
2014
Q2 | $157K | Buy |
1,654
+1,600
| +2,963% | +$112K | ﹤0.01% | 392 |
|
|
2014
Q1 | $4K | Hold |
54
| – | – | ﹤0.01% | 634 |
|
|
2013
Q4 | $4K | Hold |
54
| – | – | ﹤0.01% | 618 |
|
|
2013
Q3 | $4K | Hold |
54
| – | – | ﹤0.01% | 617 |
|
|
2013
Q2 | $4K | Buy |
+54
| New | +$3.98K | ﹤0.01% | 634 |
|
Other funds holding VRTX
Thompson Siegel & Walmsley's VRTX Position: Q2 2026 in Review
Thompson Siegel & Walmsley reduced its Vertex Pharmaceuticals (VRTX) stake by 0.45% in Q2 2026, selling an estimated $12.9K and leaving 6,408 shares worth $3.18M. The position accounts for 0.06% of the portfolio, ranked #269.
Thompson Siegel & Walmsley first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.24M in Q4 2021. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Thompson Siegel & Walmsley held 6,408 shares of Vertex Pharmaceuticals worth $3.18M as of Q2 2026.
- Thompson Siegel & Walmsley sold 29 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
- Vertex Pharmaceuticals made up 0.06% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #269 holding.
- Thompson Siegel & Walmsley first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Thompson Siegel & Walmsley's Vertex Pharmaceuticals position peaked at $9.24M in Q4 2021.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.